1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals an industry analysis of technologies, stakeholders, deals & trends

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals an industry analysis of technologies, stakeholders, deals & trends

  • May 2018
  • 294 pages
  • ID: 5402774
  • Format: PDF
  • By La Merie Publishing

Summary

Table of Contents

Search Inside

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals
T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but CAR T-cells (CAR-T) are limited to binding to cell surface antigens, while TCR T-cells (TCR-T) recognize peptides (derived from intracellular proteins) presented on the cell surface by the major histocompatibility complex (MHC) class I.
TCR-Ts have so far operated in the shadow of CAR-Ts, but may have the advantage in solid tumors. The first approved CD19-specific CAR-Ts are indicated for hematologic malignancies, but CAR-Ts were less successful against solid tumors.
This report "
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals" published in May 2018 brings you up-to-date regarding key TCR-T players, key TCR-T technologies and product candidates, business models, deals and funding opportunities. The report analyzes the TCR-T pipelines and stakeholders in the field, especially focused and diversified TCR-T companies and their relationship with academia and major pharma/biotech. The report highlights the value of TCR-T assets in terms of partnering economic conditions, acquisition prices and financing rounds.

Download Sample Pages:
TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

This report has been prepared by use of in-house databases and desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. Sources of information are provided by scientific and non-scientific references, e.g. press releases, stock exchange disclosures, presentations, annual reports, fact sheets and patent applications (with hyperlinks leading to the source of information).

Key questions answered:

Which targets are chosen for developmen of TCR-Ts?
How close are neoantigen-specific TCR-Ts to the clinic?
Which technologies are used for generation of T-Cell Receptors?
Has clinical proof-of-concept been shown for any TCR-T?
How does the TCR-T pipeline look like?
What manufacturing strategies and solutions have companies chosen?
Are next generation TCR-Ts already in development?
What are the key technologies for a successful TCR-T?
Who are the key players in the TCR-T field?
How tough is competition among TCR-T developers?
Should companies be focused on TCR-Ts only or be diversified into various adoptive T-cell therapeutics?
Which technologies and assets attract licensees?
How is the financing situation for TCR-T?
What are the key success factors for TCR-Ts?

Target audience:

Leading Pharmaceutical companies
Suppliers
Contractors
Technologists
R&D staff
Consultants
Analyst
CSO’s
CEO’s
CIO’s
COO’s
Business development managers
Investors
Governments
Agencies
Industry organisations
Banks

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
15% Off

($2451)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019

C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019’; C-C Chemokine Receptor Type 5 (CHEMR13 ...

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2019

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H2 ...

Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019

Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Respiratory Syncytial Virus Attachment Glycoprotein - Pipeline Review, H2 2019SummaryRespiratory Syncytial Virus Attachment Glycoprotein (RSV G or G) pipeline Target constitutes close to 7 molecules. The ...


ref:plp2018

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on